Drug Profile
Research programme: psoriasis therapy - OSI Pharmaceuticals/Pfizer
Alternative Names: Psoriasis therapy research programme - OSI Pharmaceuticals/ PfizerLatest Information Update: 03 Aug 2006
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals; Pfizer
- Class Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 03 Aug 2006 Discontinued - Preclinical for Psoriasis in USA (Topical)
- 11 May 2006 No development reported - Preclinical for Psoriasis in USA (Topical)
- 26 Jun 2002 This programme is still in active development